1 / 26

Global Viral and Non-Viral Vector Manufacturing Market

The global viral and non-viral vector manufacturing market was valued at $1.50 billion in 2020 and is expected to reach $27.03 billion by 2031, witnessing a CAGR of 18.54% during the forecast period 2021-2031.

bisreports
Download Presentation

Global Viral and Non-Viral Vector Manufacturing Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. res Global Viral and Non-Viral Vector Manufacturing Market Table of Content Focus on Vector Type, Application, Disease and Region Analysis and Forecast: 2021-2031 December 2021

  2. BIS Research is a leading market intelligence and technology research company. BIS Research publishes in- depth market intelligence reports focusing on the market estimations, technology analysis, emerging high- growth applications, deeply segmented granular country-level market data and other important market parameters useful in the strategic decision making for senior management. BIS Research provides multi-client reports, company profiles, databases, and custom research services. GLOBAL VIRAL AND NON-VIRAL VECTOR MANUFACTURING MARKET Copyright © 2021 BIS Research Inc. All Rights Reserved. This document contains highly confidential information and is the sole property of BIS Research. Disclosing, copying, circulating, quoting, or otherwise reproducing any or all contents of this document is strictly prohibited. Access to this information is provided exclusively for the benefit of the people or organization concerned. It may not be accessed by or offered whether for sale or otherwise to any third party. 1 All rights reserved at BIS Research Inc.

  3. Table of Content Executive Summary .......................................................................... 26 1.Product Definition ...................................................................... 36 1.1 Product Definition ............................................................................................ 36 2.Scope of Study ........................................................................... 37 2.1 Overview ........................................................................................................... 37 2.2 Segmentation of the Global Viral and Non-Viral Vector Manufacturing Market ............................................................................................................... 38 2.3 Assumptions and Limitations ......................................................................... 38 2.4 Key Questions Answered in This Report ....................................................... 39 2.5 Base Year and Forecast Period ...................................................................... 40 3.Research Methodology .............................................................. 41 3.1 Overview ........................................................................................................... 41 4.Global Viral and Non-Viral Vector Manufacturing: Market Overview ................................................................................... 47 4.1 Market Overview .............................................................................................. 47 GLOBAL VIRAL AND NON-VIRAL VECTOR MANUFACTURING MARKET 4.2 Introduction to Vectors ................................................................................... 48 4.3 Importance of Vectors ..................................................................................... 49 4.3.1Viral Vectors ................................................................................................ 50 4.3.2Non-Viral Vectors ........................................................................................ 51 4.4 Major Milestones in Vector Manufacturing .................................................... 52 4.4.1Manufacturing Process ............................................................................... 52 4.4.1.1 Upstream Bioprocessing .................................................................................... 52 4.4.1.2 Downstream Bioprocessing ............................................................................... 53 4.5 Global Viral and Non-Viral Vector Manufacturing Market Size .................... 54 4.6 Impact of COVID-19 on the Global Viral and Non-Viral Vector Manufacturing Market ..................................................................................... 55 4.6.1Disruption of the Vector Manufacturing Industry Due to COVID-19 Crisis ............................................................................................................ 55 4.6.2COVID-19 Affecting the Supply Chain of Vector-Based Therapies ......... 57 2 All rights reserved at BIS Research Inc.

  4. 4.6.2.1 Effect on Cell Therapy ....................................................................................... 58 4.6.2.2 Effect on Gene Therapy ..................................................................................... 59 4.6.3Interruption in Research and Clinical Development and Commercial Operation ..................................................................................................... 60 4.6.3.1 Research and Clinical Development .................................................................. 60 4.6.3.2 Commercial Operation and Access ................................................................... 60 4.6.4Effect of COVID-19 in Vaccine Manufacturing .......................................... 61 4.6.5Measures Taken to Address the Current Problem ................................... 64 4.6.6Navigating Crisis Recovery and Looking to the Future ........................... 65 5.Market Dynamics ....................................................................... 67 5.1 Impact Analysis ............................................................................................... 67 5.2 Overview ........................................................................................................... 67 5.3 Market Drivers .................................................................................................. 68 5.3.1Viral Vectors ................................................................................................ 68 5.3.1.1 Rapid Uptake of Viral Vector to Develop Innovative Therapies ......................... 68 5.3.1.2 Increasing Number of Clinical Studies for the Development of Gene Therapy ................................................................................................... 69 GLOBAL VIRAL AND NON-VIRAL VECTOR MANUFACTURING MARKET 5.3.1.3 Favorable Funding Scenario for Vector-Based Therapies ................................. 70 5.3.2Non-Viral Vectors ........................................................................................ 71 5.3.2.1 Increasing Adoption of Nucleic Acid Therapeutics ............................................ 71 5.3.2.2 Rise in Synergistic Activities in the Market ........................................................ 71 5.4 Market Restraints ............................................................................................. 72 5.4.1Viral Vectors ................................................................................................ 72 5.4.1.1 Unaffordable Cost of Gene Therapy .................................................................. 72 5.4.1.2 High Manufacturing Cost of Viral Vectors .......................................................... 73 5.4.1.3 Complications Associated with Large-Scale Production of Viral Vectors .......... 74 5.4.2Non-Viral Vectors ........................................................................................ 74 5.4.2.1 Low Transfection Efficiency ............................................................................... 74 5.5 Market Opportunities ....................................................................................... 75 5.5.1Viral Vectors ................................................................................................ 75 5.5.1.1 Rise in Demand for Synthetic Genes ................................................................. 75 5.5.1.2 Emergence of Next-Generation Vectors ............................................................ 75 3 All rights reserved at BIS Research Inc.

  5. 5.5.2Non-Viral Vectors ........................................................................................ 76 5.5.2.1 Limitation of Viral Vectors .................................................................................. 76 6.Industry Analysis ....................................................................... 77 6.1 Overview ........................................................................................................... 77 6.2 Regulatory Scenario ........................................................................................ 79 6.3 Patent Landscape ............................................................................................ 82 7.Competitive Landscape ............................................................. 86 7.1 Overview ........................................................................................................... 86 7.2 Key Development and Strategies ................................................................... 87 7.2.1Synergistic Activities .................................................................................. 88 7.2.2Business Expansion ................................................................................... 89 7.2.3Product Launches ....................................................................................... 90 7.2.4Mergers and Acquisitions ........................................................................... 90 7.2.5Other Development ..................................................................................... 91 7.3 Market Share Analysis (by Company), 2020 .................................................. 92 7.4 Growth Share Analysis ................................................................................... 94 GLOBAL VIRAL AND NON-VIRAL VECTOR MANUFACTURING MARKET 7.4.1Growth Share Analysis of the Global Viral and Non-Viral Vector Manufacturing Market (by Company) ........................................................ 94 7.4.2Growth Share Analysis of the Global Viral and Non-Viral Vector Manufacturing Market (by Vector Type) .................................................... 95 8.Global Viral and Non-Viral Vector Manufacturing Market (by Vector Type) .............................................................................. 97 8.1 Overview ........................................................................................................... 97 8.2 Viral Vector ....................................................................................................... 99 8.2.1Adenoviral Vector ...................................................................................... 102 8.2.2Retroviral Vector ........................................................................................ 104 8.2.3Adeno-Associated Viral Vector ................................................................ 105 8.2.4Lentiviral Vector ........................................................................................ 106 8.2.5Vaccinia Viral Vector ................................................................................. 108 8.2.6Other Viral Vector ...................................................................................... 109 4 All rights reserved at BIS Research Inc.

  6. 8.3 Non-Viral Vectors ........................................................................................... 110 8.3.1Plasmid DNA .............................................................................................. 111 8.3.2Lipid-Based Non-Viral Vector ................................................................... 113 8.3.3Polymer-Based Non-Viral Vector ............................................................. 114 8.3.4Other Non-Viral Vector (Peptide-Based and Hybrid/Combination) ....... 116 9.Global Viral and Non-Viral Vector Manufacturing Market (by Disease) .................................................................................. 118 9.1 Overview ......................................................................................................... 118 9.2 Cancer ............................................................................................................ 120 9.3 Genetic Disease ............................................................................................. 122 9.4 Infectious Disease ......................................................................................... 123 9.5 Cardiovascular Disease ................................................................................ 125 9.6 Other Diseases ............................................................................................... 127 10.Global Viral and Non-Viral Vector Manufacturing Market (by Application) ............................................................................. 129 10.1Overview ......................................................................................................... 129 GLOBAL VIRAL AND NON-VIRAL VECTOR MANUFACTURING MARKET 10.2Gene Therapy ................................................................................................. 131 10.2.1Viral Vector ................................................................................................ 132 10.2.2Non-Viral Vector ........................................................................................ 134 10.3Vaccinology .................................................................................................... 136 10.3.1Viral Vector ................................................................................................ 138 10.3.2Non-Viral Vector ........................................................................................ 139 10.4Cell Therapy ................................................................................................... 140 10.4.1Viral Vector ................................................................................................ 142 10.4.2Non-Viral Vector ........................................................................................ 143 10.5Other Applications ......................................................................................... 144 10.5.1Viral Vector ................................................................................................ 145 10.5.2Non-Viral Vector ........................................................................................ 146 11.Global Viral and Non-Viral Vector Manufacturing Market (by Region) .................................................................................... 147 5 All rights reserved at BIS Research Inc.

  7. 11.1Overview ......................................................................................................... 147 11.2North America ................................................................................................ 148 11.2.1Overview .................................................................................................... 148 11.2.2U.S. ............................................................................................................. 149 11.2.2.1 Viral Vector ...................................................................................................... 151 11.2.2.2 Non-Viral Vector .............................................................................................. 152 11.2.3Canada ....................................................................................................... 153 11.2.3.1 Viral Vector ...................................................................................................... 154 11.2.3.2 Non-Viral Vector .............................................................................................. 155 11.3Europe ............................................................................................................ 156 11.3.1Overview .................................................................................................... 156 11.3.2Germany ..................................................................................................... 157 11.3.2.1 Viral Vector ...................................................................................................... 158 11.3.2.2 Non-Viral Vector .............................................................................................. 159 11.3.3U.K. ............................................................................................................. 160 11.3.3.1 Viral Vector ...................................................................................................... 161 11.3.3.2 Non-Viral Vector .............................................................................................. 162 GLOBAL VIRAL AND NON-VIRAL VECTOR MANUFACTURING MARKET 11.3.4France ......................................................................................................... 163 11.3.4.1 Viral Vector ...................................................................................................... 164 11.3.4.2 Non-Viral Vector .............................................................................................. 165 11.3.5Italy ............................................................................................................. 166 11.3.5.1 Viral Vector ...................................................................................................... 167 11.3.5.2 Non-Viral Vector .............................................................................................. 168 11.3.6Switzerland ................................................................................................ 168 11.3.6.1 Viral Vector ...................................................................................................... 170 11.3.6.2 Non-Viral Vector .............................................................................................. 171 11.3.7Belgium ...................................................................................................... 171 11.3.7.1 Viral Vector ...................................................................................................... 173 11.3.7.2 Non-Viral Vector .............................................................................................. 173 11.3.8Spain ........................................................................................................... 174 11.3.8.1 Viral Vector ...................................................................................................... 175 6 All rights reserved at BIS Research Inc.

  8. 11.3.8.2 Non-Viral Vector .............................................................................................. 176 11.3.9Rest-of-Europe........................................................................................... 176 11.3.9.1 Viral Vector ...................................................................................................... 178 11.3.9.2 Non-Viral Vector .............................................................................................. 178 11.4Asia-Pacific .................................................................................................... 179 11.4.1Overview .................................................................................................... 179 11.4.2China .......................................................................................................... 180 11.4.2.1 Viral Vector ...................................................................................................... 182 11.4.2.2 Non-Viral Vector .............................................................................................. 182 11.4.3Australia ..................................................................................................... 183 11.4.3.1 Viral Vector ...................................................................................................... 185 11.4.3.2 Non-Viral Vector .............................................................................................. 185 11.4.4Japan .......................................................................................................... 186 11.4.4.1 Viral Vector ...................................................................................................... 187 11.4.4.2 Non-Viral Vector .............................................................................................. 188 11.4.5India ............................................................................................................ 188 11.4.5.1 Viral Vector ...................................................................................................... 190 GLOBAL VIRAL AND NON-VIRAL VECTOR MANUFACTURING MARKET 11.4.5.2 Non-Viral Vector .............................................................................................. 191 11.4.6South Korea ............................................................................................... 191 11.4.6.1 Viral Vector ...................................................................................................... 193 11.4.6.2 Non-Viral Vector .............................................................................................. 193 11.4.7Singapore ................................................................................................... 194 11.4.7.1 Viral Vector ...................................................................................................... 195 11.4.7.2 Non-Viral Vector .............................................................................................. 196 11.4.8Rest-of-Asia-Pacific ................................................................................... 196 11.4.8.1 Viral Vector ...................................................................................................... 197 11.4.8.2 Non-Viral Vector .............................................................................................. 198 11.5Rest-of-the-World .......................................................................................... 199 11.5.1Overview .................................................................................................... 199 11.5.1.1 Viral Vector ...................................................................................................... 200 11.5.1.2 Non-Viral Vector .............................................................................................. 201 7 All rights reserved at BIS Research Inc.

  9. 12.Company Profiles ..................................................................... 202 12.1Overview ......................................................................................................... 202 12.2Boehringer Ingelheim .................................................................................... 203 12.2.1Company Overview ................................................................................... 203 12.2.1.1 Role of Boehringer Ingelheim in the Global Viral and Non-Viral Vector Manufacturing Market ............................................................................ 203 12.2.1.2 Product Portfolio .............................................................................................. 203 12.2.2SWOT Analysis .......................................................................................... 204 12.3Catalent, Inc. .................................................................................................. 205 12.3.1Company Overview ................................................................................... 205 12.3.1.1 Role of Catalent, Inc. in the Global Viral and Non-Viral Vector Manufacturing Market ............................................................................ 205 12.3.1.2 Product Portfolio .............................................................................................. 206 12.3.2Financials ................................................................................................... 207 12.3.3Key Insights about Financial Health of the Company ............................ 208 12.3.4SWOT Analysis .......................................................................................... 209 12.4FUJIFILM Holdings Corporation ................................................................... 210 GLOBAL VIRAL AND NON-VIRAL VECTOR MANUFACTURING MARKET 12.4.1Company Overview ................................................................................... 210 12.4.1.1 Role of FUJIFILM Holdings Corporation in the Global Viral and Non-Viral Vector Manufacturing Market ................................................................ 210 12.4.1.2 Product Portfolio .............................................................................................. 211 12.4.2Financials ................................................................................................... 211 12.4.3Key Insights about Financial Health of the Company ............................ 213 12.4.4SWOT Analysis .......................................................................................... 214 12.5Danaher Corporation ..................................................................................... 215 12.5.1Company Overview ................................................................................... 215 12.5.2Role of Danaher Corporation in the Global Viral and Non-Viral Vector Manufacturing Market ................................................................... 215 12.5.2.1 Product Portfolio .............................................................................................. 216 12.5.3Financials ................................................................................................... 217 12.5.4Key Insights about Financial Health of the Company ............................ 218 12.5.5SWOT Analysis .......................................................................................... 219 8 All rights reserved at BIS Research Inc.

  10. 12.6Genscript Biotech Corporation .................................................................... 220 12.6.1Company Overview ................................................................................... 220 12.6.1.1 Role of Genscript Biotech Corporation in the Global Viral and Non-Viral Vector Manufacturing Market ................................................................ 220 12.6.1.2 Product Portfolio .............................................................................................. 221 12.6.2Financials ................................................................................................... 221 12.6.3Key Insights about Financial Health of the Company ............................ 223 12.6.4SWOT Analysis .......................................................................................... 224 12.7Lonza Group AG ............................................................................................ 225 12.7.1Company Overview ................................................................................... 225 12.7.1.1 Role of Lonza Group AG in the Global Viral and Non-Viral Vector Manufacturing Market ............................................................................ 225 12.7.1.2 Product Portfolio .............................................................................................. 226 12.7.2Financials ................................................................................................... 226 12.7.3Key Insights about Financial Health of the Company ............................ 228 12.7.4SWOT Analysis .......................................................................................... 229 12.8Merck KGaA Inc. ............................................................................................ 230 GLOBAL VIRAL AND NON-VIRAL VECTOR MANUFACTURING MARKET 12.8.1Company Overview ................................................................................... 230 12.8.1.1 Role of Merck KGaA Inc. in the Global Viral and Non-Viral Vector Manufacturing Market ............................................................................ 230 12.8.1.2 Product Portfolio .............................................................................................. 231 12.8.2Financials ................................................................................................... 231 12.8.3Key Insights about Financial Health of the Company ............................ 233 12.8.4SWOT Analysis .......................................................................................... 233 12.9Oxford Biomedica plc .................................................................................... 234 12.9.1Company Overview ................................................................................... 234 12.9.1.1 Role of Oxford Biomedica plc in the Global Viral and Non-Viral Vector Manufacturing Market ............................................................................ 234 12.9.1.2 Product Portfolio .............................................................................................. 235 12.9.2Financials ................................................................................................... 235 12.9.3Key Insights about Financial Health of the Company ............................ 237 12.9.4SWOT Analysis .......................................................................................... 238 9 All rights reserved at BIS Research Inc.

  11. 12.10Sartorius AG ................................................................................................... 239 12.10.1 Company Overview ............................................................................. 239 12.10.1.1 Role of Sartorius AG in the Global Viral and Non-Viral Vector Manufacturing Market ............................................................................ 239 12.10.1.2 Product Portfolio .............................................................................................. 240 12.10.2 Financials ............................................................................................ 240 12.10.3 Key Insights about Financial Health of the Company ...................... 242 12.10.4 SWOT Analysis .................................................................................... 243 12.11Takara Bio Inc. ............................................................................................... 244 12.11.1 Company Overview ............................................................................. 244 12.11.1.1 Role of Takara Bio Inc. in the Global Viral and Non-Viral Vector Manufacturing Market ............................................................................ 244 12.11.1.2 Product Portfolio .............................................................................................. 245 12.11.2 Financials ............................................................................................ 245 12.11.3 Key Insights about Financial Health of the Company ...................... 247 12.11.4 SWOT Analysis .................................................................................... 248 12.12Thermo Fisher Scientific Inc. ........................................................................ 249 GLOBAL VIRAL AND NON-VIRAL VECTOR MANUFACTURING MARKET 12.12.1 Company Overview ............................................................................. 249 12.12.1.1 Role of Thermo Fisher Scientific, Inc. in the Global Viral and Non-Viral Vector Manufacturing Market ................................................................ 249 12.12.1.2 Product Portfolio .............................................................................................. 250 12.12.2 Financials ............................................................................................ 251 12.12.3 Key Insights about Financial Health of the Company ...................... 252 12.12.4 SWOT Analysis .................................................................................... 253 12.13Wuxi AppTec .................................................................................................. 254 12.13.1 Company Overview ............................................................................. 254 12.13.1.1 Role of Wuxi AppTec in Global Viral and Non-Viral Vector Manufacturing Market .................................................................................................... 254 12.13.1.2 Product Portfolio .............................................................................................. 255 12.13.2 Financials ............................................................................................ 255 12.13.3 Key Insights about Financial Health of the Company ...................... 257 12.13.4 SWOT Analysis .................................................................................... 258 10 All rights reserved at BIS Research Inc.

  12. 12.14Acuitas Therapeutics .................................................................................... 259 12.14.1 Company Overview ............................................................................. 259 12.14.1.1 Role of Acuitas Therapeutics in the Global Viral and Non-Viral Vector Manufacturing Market ............................................................................ 259 12.14.1.2 Product Portfolio .............................................................................................. 259 12.14.2 SWOT Analysis .................................................................................... 260 12.15Evonik Industries AG .................................................................................... 261 12.15.1 Company Overview ............................................................................. 261 12.15.1.1 Role of Evonik Industries AG in the Global Viral and Non-Viral Vector Manufacturing Market ............................................................................ 261 12.15.1.2 Product Portfolio .............................................................................................. 262 12.15.2 Financials ............................................................................................ 262 12.15.3 Key Insights about Financial Health of the Company ...................... 264 12.15.4 SWOT Analysis .................................................................................... 265 12.16Exelead, Inc. ................................................................................................... 266 12.16.1 Company Overview ............................................................................. 266 12.16.1.1 Role of Exelead, Inc. in the Global Viral and Non-Viral Vector Manufacturing Market ............................................................................ 266 GLOBAL VIRAL AND NON-VIRAL VECTOR MANUFACTURING MARKET 12.16.1.2 Product Portfolio .............................................................................................. 266 12.16.2 SWOT Analysis .................................................................................... 267 12.17Entos Pharmaceuticals ................................................................................. 268 12.17.1 Company Overview ............................................................................. 268 12.17.1.1 Role of Entos Pharmaceuticals in the Global Viral and Non-Viral Vector Manufacturing Market ............................................................................ 268 12.17.1.2 Product Portfolio .............................................................................................. 268 12.17.2 SWOT Analysis .................................................................................... 269 12.18Genevant Sciences GmbH ............................................................................ 270 12.18.1 Company Overview ............................................................................. 270 12.18.1.1 Role of Genevant Sciences GmbH in the Global Viral and Non-Viral Vector Manufacturing Market ................................................................ 270 12.18.1.2 Product Portfolio .............................................................................................. 270 12.18.2 SWOT Analysis .................................................................................... 271 11 All rights reserved at BIS Research Inc.

  13. 12.19T&T Scientific Corporation ........................................................................... 272 12.19.1 Company Overview ............................................................................. 272 12.19.1.1 Role of T&T Scientific Corporation in the Global Viral and Non-Viral Vector Manufacturing Market ................................................................ 272 12.19.1.2 Product Portfolio .............................................................................................. 272 12.19.2 SWOT Analysis .................................................................................... 273 12.20Moderna, Inc. .................................................................................................. 274 12.20.1 Company Overview ............................................................................. 274 12.20.1.1 Role of Moderna, Inc. in the Global Viral and Non-Viral Vector Manufacturing Market ............................................................................ 274 12.20.1.2 Product Portfolio .............................................................................................. 275 12.20.2 Financials ............................................................................................ 276 12.20.3 Key Insights about Financial Health of the Company ...................... 277 12.20.4 SWOT Analysis .................................................................................... 278 12.21CureVac N.V. .................................................................................................. 279 12.21.1 Company Overview ............................................................................. 279 12.21.1.1 Role of CureVac N.V in the Global Viral and Non-Viral Vector Manufacturing Market ............................................................................ 279 GLOBAL VIRAL AND NON-VIRAL VECTOR MANUFACTURING MARKET 12.21.1.2 Product Portfolio .............................................................................................. 279 12.21.2 Financials ............................................................................................ 280 12.21.3 Key Insights about Financial Health of the Company ...................... 281 12.21.4 SWOT Analysis .................................................................................... 282 12 All rights reserved at BIS Research Inc.

  14. List of Figures Figure 1:Global Viral and Non-Viral Vector Manufacturing Market (by Region), 2020 and 2031 Figure 2:Key Players of the Global Viral and Non-Viral Vector Manufacturing Market Figure 3:Drivers, Challenges, and Opportunities of the Global Viral Vector and Non-Viral Vector Manufacturing Market Figure 4:Share of Key Developments and Strategies, January 2018-October 2021 Figure 5:Global Viral and Non-Viral Vector Manufacturing Market (by Vector Type), $Million, 2020 and 2031 Figure 6:Global Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031 Figure 7:Global Viral and Non-Viral Vector Manufacturing Market (by Disease), 2020 and 2031 Figure 8:Global Viral and Non-Viral Vector Manufacturing Market (by Application), 2020 and 2031 Figure 9:Global Viral and Non-Viral Vector Manufacturing Market Segmentation Figure 10:Global Viral and Non-Viral Vector Manufacturing Market Research Methodology Figure 11:Primary Research Figure 12:Secondary Research Figure 13:Data Triangulation Figure 14:Bottom-Up Approach (Segment-Wise Analysis) Figure 15:Top-Down Approach (Segment-Wise Analysis) Figure 16:Assumptions and Limitations GLOBAL VIRAL AND NON-VIRAL VECTOR MANUFACTURING MARKET Figure 17:Mechanism of Action of Vectors Figure 18:Evolutionary History of Vectors Figure 19:Typical Production Methods of Viral Vectors and Plasmids Figure 20:Global Viral and Non-Viral Vector Manufacturing Market, $Billion, 2020-2031 Figure 21:Pre- COVID-19 and Post-COVID-19 Scenario of the Global Viral and Non-Viral Vector Manufacturing Market, 2017-2025 Figure 22:Long, Complex, and Highly Controlled Supply Chain of Cell Therapy Figure 23:Less-Complex Supply Chain of Gene Therapy Figure 24:Areas of Disruption in Cell Therapy Industry Figure 25:Areas of Disruption in Gene Therapy Industry Figure 26:Key Areas of Disruption in Commercial Operation Figure 27:Measures to Navigate Crisis Recovery Figure 28:Impact Analysis Figure 29:Workflow Associated with Biomanufacturing for the Commercialization of Viral and Non- Viral Vector Products Figure 30:Competitive Landscape, January 2018-October 2021 Figure 31:Share of Key Development and Strategy, January 2018-October 2021 Figure 32:Share of Synergistic Activities (by Company), January 2018-October 2021 13 All rights reserved at BIS Research Inc.

  15. Figure 33:Share of Business Expansion Activities (by Company), January 2018-October 2021 Figure 34:Share of Product Launches (by Company), January 2018-October 2021 Figure 35:Share of Mergers and Acquisitions (by Company), January 2018-October 2021 Figure 36:Share of Other Key Developments (by Company), January 2018-October 2021 Figure 37:Market Share Analysis of Global Viral and Non-Viral Vector Manufacturing Market (by Company), 2020 Figure 38:Growth Share Analysis for Global Viral and Non-Viral Vector Manufacturing Market (by Company), 2020 Figure 39:Growth Share Analysis for the Global Viral and Non-Viral Vector Manufacturing Market (by Vector Type), 2020 Figure 40:Global Viral and Non-Viral Vector Manufacturing Market Segmentation (by Vector Type) Figure 41:Global Viral and Non-Viral Vector Manufacturing Market (by Viral and Non-Viral Vector), $Million, 2020 and 2031 Figure 42:Global Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020- 2031 Figure 43:Global Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031 Figure 44:Global Viral and Non-Viral Vector Manufacturing Market for Adenoviral Vector $Million, 2020-2031 Figure 45:Global Viral and Non-Viral Vector Manufacturing Market for Retroviral Vector $Million, 2020- 2031 Figure 46:Global Viral and Non-Viral Vector Manufacturing Market for Adeno-Associated Viral Vector, $Million, 2020-2031 GLOBAL VIRAL AND NON-VIRAL VECTOR MANUFACTURING MARKET Figure 47:Global Viral and Non-Viral Vector Manufacturing Market for Lentiviral Vector, 2020-2031 Figure 48:Global Viral and Non-Viral Vector Manufacturing Market for Vaccinia Viral Vector, $Million, 2020-2031 Figure 49:Global Viral and Non-Viral Vector Manufacturing Market for Other Viral Vector, $Million, 2020-2031 Figure 50:Global Viral and Non-Viral Vector Manufacturing Market for Non-Viral Vectors, 2020-2031 Figure 51:Global Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031 Figure 52:Global Viral and Non-Viral Vector Manufacturing Market for Plasmid DNA, $Million, 2020- 2031 Figure 53:Different Types of Lipid-Based Non-Viral Vectors Figure 54:Viral and Non-Viral Vector Manufacturing Market for Lipid-Based Non-Viral Vectors, $Million, 2020-2031 Figure 55:Different Types of Polymers Used as Delivery Systems Figure 56:Viral and Non-Viral Vector Manufacturing Market for Polymer-Based Non-Viral Vector, $Million, 2020-2031 Figure 57:Viral and Non-Viral Vector Manufacturing Market for Other Non-Viral Vector, $Million, 2020- 2031 14 All rights reserved at BIS Research Inc.

  16. Figure 58:Global Viral and Non-Viral Vector Manufacturing Market Segmentation (by Disease) Figure 59:Global Viral and Non-Viral Vector Manufacturing Market (by Disease) Figure 60:Global Viral and Non-Viral Vector Manufacturing Market for Cancer, $Million, 2020-2031 Figure 61:List of Approved Human Gene Transfer Trials for Monogenic Disorders Figure 62:Global Viral and Non-Viral Vector Manufacturing Market for Genetic Disease, $Million, 2020-2031 Figure 63:Global Viral and Non-Viral Vector Manufacturing Market for Infectious Disease, $Million, 2020-2031 Figure 64:Global Viral and Non-Viral Vector Manufacturing Market for Cardiovascular Disease, $Million, 2020-2031 Figure 65:Global Viral and Non-Viral Vector Manufacturing Market for Other Diseases, 2020-2031 Figure 66:Global Viral and Non-Viral Vector Manufacturing Market Segmentation (by Application) Figure 67:Global Viral and Non-Viral Vector Manufacturing Market (by Application), 2020 and 2031 Figure 68:Global Viral and Non-Viral Vector Manufacturing Market for Gene Therapy, $Million, 2020- 2031 Figure 69:Gene Therapy: Viral Vs. Non-Viral Vector Manufacturing Market, $Million, 2020-2031 Figure 70:Global Viral and Non-Viral Vector Manufacturing Market for Gene Therapy (by Viral Vector), $Million, 2020 and 2031 Figure 71:Global Viral and Non-Viral Vector Manufacturing Market for Gene Therapy (by Non-Viral Vector), $Million, 2020 and 2031 Figure 72:Global Viral and Non-Viral Vector Manufacturing Market for Vaccinology, $Million, 2020- 2031 GLOBAL VIRAL AND NON-VIRAL VECTOR MANUFACTURING MARKET Figure 73:Vaccinology: Viral Vs. Non-Viral Vector Manufacturing Market, $Million, 2020-2031 Figure 74:Global Viral and Non-Viral Vector Manufacturing Market for Vaccinology (by Viral Vector), $Million, 2020 and 2031 Figure 75:Global Viral and Non-Viral Vector Manufacturing Market for Vaccinology (by Non-Viral Vector), 2020 and 2031 Figure 76:Global Viral and Non-Viral Vector Manufacturing Market for Cell Therapy, $Million, 2020- 2031 Figure 77:Cell Therapy: Viral Vs. Non-Viral Vector Manufacturing Market, $Million, 2020-2031 Figure 78:Global Viral and Non-Viral Vector Manufacturing Market for Cell Therapy (by Viral Vector), $Million, 2020 and 2031 Figure 79:Global Viral and Non-Viral Vector Manufacturing Market for Cell Therapy (by Non-Viral Vector), $Million, 2020 and 2031 Figure 80:Global Viral and Non-Viral Vector Manufacturing Market for Other Applications, $Million, 2020-2031 Figure 81:Other Applications: Viral Vs. Non-Viral Vector Manufacturing Market, $Million, 2020-2031 Figure 82:Global Viral and Non-Viral Vector Manufacturing Market for Other Applications (by Viral Vector), $Million, 2020 and 2031 Figure 83:Global Viral and Non-Viral Vector Manufacturing Market for Other Applications (by Non-Viral Vector), $Million, 2020 and 2031 15 All rights reserved at BIS Research Inc.

  17. Figure 84:North America: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031 Figure 85:U.S.: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031 Figure 86:U.S.: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020- 2031 Figure 87:U.S.: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031 Figure 88:U.S.: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031 Figure 89:Canada: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031 Figure 90:Canada: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031 Figure 91:Canada: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031 Figure 92:Canada: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031 Figure 93:Europe: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031 Figure 94:Germany: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031 Figure 95:Germany: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031 Figure 96:Germany: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031 Figure 97:Germany: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031 GLOBAL VIRAL AND NON-VIRAL VECTOR MANUFACTURING MARKET Figure 98:U.K.: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031 Figure 99:U.K.: Viral Vs Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020- 2031 Figure 100: U.K.: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031 Figure 101: U.K.: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031 Figure 102: France: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031 Figure 103: France: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031 Figure 104: France: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031 Figure 105: France: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031 Figure 106: Italy: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031 Figure 107: Italy: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), 2020-2031 Figure 108: Italy: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031 16 All rights reserved at BIS Research Inc.

  18. Figure 109: Italy: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031 Figure 110: Switzerland: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031 Figure 111: Switzerland: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031 Figure 112: Switzerland: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031 Figure 113: Switzerland: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031 Figure 114: Belgium: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031 Figure 115: Belgium: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031 Figure 116: Belgium: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031 Figure 117: Belgium: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), 2020 and 2031 Figure 118: Spain: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031 Figure 119: Spain: Viral and Non-Viral Vector Manufacturing Market, (Viral Vs. Non-Viral), $Million, 2020-2031 Figure 120: Spain: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031 Figure 121: Spain: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031 GLOBAL VIRAL AND NON-VIRAL VECTOR MANUFACTURING MARKET Figure 122: Rest-of-Europe: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031 Figure 123: Rest-of-Europe: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031 Figure 124: Rest-of-Europe: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031 Figure 125: Rest-of-Europe: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031 Figure 126: Asia-Pacific: Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031 Figure 127: China: Viral Vector and Non-Viral Vector Manufacturing Market, $Million 2020-2031 Figure 128: China: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031 Figure 129: China: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031 Figure 130: China: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031 Figure 131: Australia: Viral Vector and Non-Viral Vector Manufacturing Market, $Million 2020-2031 Figure 132: Australia: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031 17 All rights reserved at BIS Research Inc.

  19. Figure 133: Australia: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031 Figure 134: Australia: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031 Figure 135: Japan: Viral Vector and Non-Viral Vector Manufacturing Market, $Million 2020-2031 Figure 136: Japan: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031 Figure 137: Japan: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031 Figure 138: Japan: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031 Figure 139: India: Viral Vector and Non-Viral Vector Manufacturing Market, $Million 2020-2031 Figure 140: India: Viral vs Non-Viral Vector Manufacturing Market, $Million, 2020-2031 Figure 141: India: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031 Figure 142: India: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031 Figure 143: South Korea: Viral Vector and Non-Viral Vector Manufacturing Market, $Million, 2020- 2031 Figure 144: South Korea: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031 Figure 145: South Korea: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031 GLOBAL VIRAL AND NON-VIRAL VECTOR MANUFACTURING MARKET Figure 146: South Korea: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031 Figure 147: Singapore: Viral Vector and Non-Viral Vector Manufacturing Market, $Million 2020-2031 Figure 148: Singapore: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-Viral), $Million, 2020-2031 Figure 149: Singapore: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031 Figure 150: Singapore: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020-2031 Figure 151: Rest-of-Asia-Pacific: Viral Vector and Non-Viral Vector Manufacturing Market, $Million, 2020-2031 Figure 152: Rest-of-Asia-Pacific: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non- Viral Vector), $Million, 2020-2031 Figure 153: Rest-of-Asia-Pacific: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031 Figure 154: Rest-of-Asia-Pacific: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031 Figure 155: Rest-of-the-World Viral and Non-Viral Vector Manufacturing Market, $Million, 2020-2031 18 All rights reserved at BIS Research Inc.

  20. Figure 156: Rest-of-the-World: Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non- Viral), $Million, 2020-2031 Figure 157: Rest-of-the-World: Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), $Million, 2020 and 2031 Figure 158: Rest-of-the-World: Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), $Million, 2020 and 2031 Figure 159: Shares of Key Company Profiles Figure 160: Boehringer Ingelheim: Service Portfolio Figure 161: Boehringer Ingelheim: SWOT Analysis Figure 162: Catalent, Inc.: Service/Product Portfolio Figure 163: Catalent, Inc.: Overall Financials, $Million, 2019-2021 Figure 164: Catalent, Inc.: Revenue (by Segment), $Million, 2019-2021 Figure 165: Catalent, Inc.: Revenue (by Region), $Million, 2019-2021 Figure 166: Catalent, Inc.: R&D Expenditure, $Million, 2019-2021 Figure 167: Catalent, Inc.: SWOT Analysis Figure 168: FUJIFILM Holdings Corporation: Service/Product Portfolio Figure 169: FUJIFILM Holdings Corporation: Overall Financials, $Million, 2018-2020 Figure 170: FUJIFILM Holdings Corporation: Revenue (by Segment), $Million, 2018-2020 Figure 171: FUJIFILM Holdings Corporation: Revenue (by Region), $Million, 2018-2020 Figure 172: FUJIFILM Holdings Corporation: R&D Expenditure, $Million, 2018-2020 Figure 173: FUJIFILM Holdings Corporation: SWOT Analysis Figure 174: Danaher Corporation: Service/Product Portfolio GLOBAL VIRAL AND NON-VIRAL VECTOR MANUFACTURING MARKET Figure 175: Danaher Corporation: Overall Financials, $Million, 2018-2020 Figure 176: Danaher Corporation: Revenue (by Segment), $Million, 2018-2020 Figure 177: Danaher Corporation: Revenue (by Region), $Million, 2018-2020 Figure 178: Danaher Corporation: R&D Expenditure, $Million, 2018-2020 Figure 179: Danaher Corporation: SWOT Analysis Figure 180: Genscript Biotech Corporation: Service/Product Portfolio Figure 181: Genscript Biotech Corporation: Overall Financials, $Million, 2018-2020 Figure 182: Genscript Biotech Corporation: Revenue (by Segment), $Million, 2018-2020 Figure 183: Genscript Biotech Corporation: Revenue (by Region), $Million, 2018-2020 Figure 184: Genscript Biotech Corporation: R&D Expenditure, $Million, 2018-2020 Figure 185: Genscript Biotech Corporation: SWOT Analysis Figure 186: Lonza Group AG: Service/Product Portfolio Figure 187: Lonza Group AG: Overall Financials, $Million, 2018-2020 Figure 188: Lonza Group AG: Revenue (by Segment), $Million, 2018-2020 Figure 189: Lonza Group AG: Revenue (by Region), $Million, 2018-2020 Figure 190: Lonza Group AG: R&D Expenditure, $Million, 2018-2020 Figure 191: Lonza Group AG: SWOT Analysis 19 All rights reserved at BIS Research Inc.

  21. Figure 192: Merck KGaA Inc.: Service/Product Portfolio Figure 193: Merck KGaA Inc.: Overall Financials, $Million, 2018-2020 Figure 194: Merck KGaA Inc.: Revenue (by Segment), $Million, 2018-2020 Figure 195: Merck KGaA Inc.: Revenue (by Region), $Million, 2018-2020 Figure 196: Merck KGaA Inc.: R&D Expenditure, $Million, 2018-2020 Figure 197: Merck KGaA Inc.: SWOT Analysis Figure 198: Oxford Biomedica plc: Service/Product Portfolio Figure 199: Oxford Biomedica plc: Overall Financials, $Million, 2018-2020 Figure 200: Oxford Biomedica plc: Revenue (by Segment), $Million, 2018-2020 Figure 201: Oxford Biomedica plc: Revenue (by Region), $Million, 2018-2020 Figure 202: Oxford Biomedica plc: R&D Expenditure, $Million, 2018-2020 Figure 203: Oxford Biomedica plc: SWOT Analysis Figure 204: Sartorius AG: Service/Product Portfolio Figure 205: Sartorius AG: Overall Financials, $Million, 2018-2020 Figure 206: Sartorius AG: Revenue (by Segment), $Million, 2018-2020 Figure 207: Sartorius AG: Revenue (by Region), $Million, 2018-2020 Figure 208: Sartorius AG: R&D Expenditure, $Million, 2018-2020 Figure 209: Sartorius AG: SWOT Analysis Figure 210: Takara Bio Inc.: Service/Product Portfolio Figure 211: Takara Bio Inc.: Overall Financials, $Million, 2018-2020 Figure 212: Takara Bio Inc.: Revenue (by Segment), $Million, 2018-2020 GLOBAL VIRAL AND NON-VIRAL VECTOR MANUFACTURING MARKET Figure 213: Takara Bio Inc.: Revenue (by Region), $Million, 2018-2020 Figure 214: Takara Bio Inc.: R&D Expenditure, $Million, 2018-2020 Figure 215: Takara Bio Inc.: SWOT Analysis Figure 216: Thermo Fisher Scientific, Inc.: Service/Product Portfolio Figure 217: Thermo Fisher Scientific, Inc.: Overall Financials, $Million, 2018-2020 Figure 218: Thermo Fisher Scientific, Inc.: Revenue (by Segment), $Million, 2018-2020 Figure 219: Thermo Fisher Scientific, Inc.: Revenue (by Region), $Million, 2018-2020 Figure 220: Thermo Fisher Scientific, Inc.: R&D Expenditure, $Million, 2018-2020 Figure 221: Thermo Fisher Scientific, Inc.: SWOT Analysis Figure 222: Wuxi AppTec: Service/Product Portfolio Figure 223: Wuxi AppTec: Overall Financials, $Million, 2018-2020 Figure 224: Wuxi AppTec: Revenue (by Segment), $Million, 2018-2020 Figure 225: Wuxi AppTec: Revenue (by Region), $Million, 2018-2020 Figure 226: Wuxi AppTec: R&D Expenditure, $Million, 2018-2020 Figure 227: Wuxi AppTec: SWOT Analysis Figure 228: Acuitas Therapeutics: Service/Product Portfolio Figure 229: Acuitas Therapeutics: SWOT Analysis Figure 230: Evonik Industries AG: Service/Product Portfolio 20 All rights reserved at BIS Research Inc.

  22. Figure 231: Evonik Industries AG: Overall Financials, $Million, 2018-2020 Figure 232: Evonik Industries AG: Revenue (by Segment), $Million, 2018-2020 Figure 233: Evonik Industries AG: Revenue (by Region), $Million, 2018-2020 Figure 234: Evonik Industries AG: R&D Expenditure, $Million, 2018-2020 Figure 235: Evonik Industries AG: SWOT Analysis Figure 236: Exelead, Inc.: Service/Product Portfolio Figure 237: Exelead, Inc.: SWOT Analysis Figure 238: Entos Pharmaceuticals: Service/Product Portfolio Figure 239: Entos Pharmaceuticals: SWOT Analysis Figure 240: Genevant Sciences GmbH: Service/Product Portfolio Figure 241: Genevant Sciences GmbH: SWOT Analysis Figure 242: T&T Scientific Corporation: Service/Product Portfolio Figure 243: T&T Scientific Corporation: SWOT Analysis Figure 244: Moderna, Inc.: Service/Product Portfolio Figure 245: Moderna, Inc.: Overall Financials, $Million, 2018-2020 Figure 246: Moderna, Inc.: Revenue (by Region), $Million, 2018-2020 Figure 247: Moderna, Inc.: R&D Expenditure, $Million, 2018-2020 Figure 248: Moderna, Inc.: SWOT Analysis Figure 249: CureVac N.V.: Product Portfolio Figure 250: CureVac N.V.: Overall Financials, $Million, 2018-2020 Figure 251: CureVac N.V.: Revenue (by Region), $Million, 2018-2020 GLOBAL VIRAL AND NON-VIRAL VECTOR MANUFACTURING MARKET Figure 252: CureVac N.V.: R&D Expenditure, $Million, 2018-2020 Figure 253: CureVac N.V.: SWOT Analysis 21 All rights reserved at BIS Research Inc.

  23. List of Tables Table 1: Leading Segments of the Global Viral and Non-Viral Vector Manufacturing Market, 2020 and 2031 Table 2: Advantages and Disadvantages of Viral Vectors Table 3: Advantages and Disadvantages of Non-Viral Vectors Table 4: COVID-19 Candidate Viral Vector Vaccines in Clinical Stage (as of 31st July 2020) Table 5: COVID-19 Candidate Viral Vector Vaccines in Preclinical Stage (as of 31 July 2020) Table 6: Recent Approvals for Gene Therapy Table 7: Companies Offering Gene Therapies and Their Cost Table 8: Global Regulatory Scenario Table 9: Patents Related to Viral Vectors (January 2018-February 2021) Table 10:Patents Related to Non-Viral Vectors (January 2018-February 2021) Table 11:Examples of Viral Vectors Used in Gene Therapy Table 12:List of Non-Viral Vector-Based Vaccines against Infectious Diseases Table 13:Features of Vectors Used in Cardiovascular Therapy Table 14:Examples of Clinical Trials Using Viral Vectors Table 15:List of Clinical Trials Using Non-Viral Vectors Table 16:Advantages and Disadvantages Associated with Major Viral Vectors GLOBAL VIRAL AND NON-VIRAL VECTOR MANUFACTURING MARKET 22 All rights reserved at BIS Research Inc.

  24. BIS Research Offerings: We are on a mission to harness the potential of disruptive technologies to make businesses thrive in today’s digital age. We have a vision to be a leading and a preferred knowledge partner for corporates and institutions worldwide and assist them with market intelligence in the area of emerging technologies, advisories, and other innovative solutions. GLOBAL VIRAL AND NON-VIRAL VECTOR MANUFACTURING MARKET Know More Know More Know More Know More 23 All rights reserved at BIS Research Inc.

  25. Disclaimer BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth. This document and its contents are confidential and may not be further distributed, published or reproduced, in whole or in part, by any medium or in any form for any purpose, without the express written consent of BIS Research Inc. Customer will not disclose the contents of the report, whether directly in any media or indirectly through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce Information in legal proceedings. Market reports are based on expectations, estimates and projections as of the date such information is available. Any recommendation contained in this report may not be suitable for all investors or businesses. The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while considered reasonable by BIS Research Inc. as of the date of such statements, are inherently subject to market fluctuations and business, economic and competitive uncertainties and contingencies For more details regarding permission, please contact us: Email: sales@bisresearch.com Tel: +1 510 404 8135 GLOBAL VIRAL AND NON-VIRAL VECTOR MANUFACTURING MARKET 24 All rights reserved at BIS Research Inc.

  26. GLOBAL VIRAL AND NON-VIRAL VECTOR MANUFACTURING MARKET BIS RESEARCH INC. 39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686 E-mail: hello@bisresearch.com | Call Us: +1-510-404-8135 Global Delivery Center Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway, Sector 126, Noida, U.P., 201303, India Tel: +91 120 4261540 / 4261544 www.bisresearch.com 25 All rights reserved at BIS Research Inc. BIS RESEARCH INC.

More Related